One of a select few global players making the devices that deliver the world's fastest-growing drugs
A decades-old plastics manufacturer in India finds itself at an unexpected crossroads of industrial history: as blockbuster obesity and diabetes drugs lose patent protection across major markets, Shaily Engineering Plastics has quietly positioned itself as one of the few companies in the world capable of building the devices that will deliver the next generation of generic treatments to millions of patients. Motilal Oswal's initiation of coverage with a 26% upside target is less a routine analyst call than a recognition that a company once defined by supplying IKEA and Unilever is now being reshaped by the global weight-loss drug boom. The transformation raises a question as old as industrial capitalism itself: when a business reinvents its identity around a single powerful wave, how much of the reward is vision, and how much is timing?
- Semaglutide's patent expiry across India, Brazil, and Canada from March 2026 is set to unleash a wave of generic drug manufacturers who will urgently need specialized injection delivery devices — and Shaily is already named as sole supplier for most of these engagements.
- Healthcare contributes just 10% of Shaily's revenue today, creating a dramatic gap between the company's current identity and the one analysts believe it is rapidly becoming.
- The company is committing over Rs 600 crore in capacity expansion to meet projected demand, a capital bet that signals confidence but also concentrates risk on a single transformative thesis.
- Fiscal 2026 results — 26% revenue growth, 82% net profit surge, EBITDA margins expanding from 22.4% to 28.2% — suggest the transition is already generating real financial momentum, not just promise.
- Analysts flag that valuations have already moved sharply higher, meaning any execution stumble — a delayed contract or manufacturing shortfall — could trigger a painful repricing of the stock's ambitious trajectory.
For nearly four decades, Shaily Engineering Plastics built a quiet, steady business supplying precision plastic components to global household names — IKEA, Unilever, Procter & Gamble. The margins were modest, the work reliable. But inside the company's healthcare division, a more consequential transformation has been taking shape, one that Motilal Oswal has now formalized with a buy recommendation and a target price of Rs 3,404 — implying 26% upside from current levels.
The pivot centers on injection delivery devices: insulin pens, GLP-1 pens, the specialized equipment pharmaceutical companies need to put their drugs into patients' hands. Shaily is among a small group of global manufacturers with the expertise to produce these complex components, and that positioning becomes critical as semaglutide — the active ingredient in the world's most talked-about weight-loss and diabetes drugs — loses patent protection in India, Brazil, and Canada starting March 2026. Generic manufacturers entering those markets will need delivery devices. According to Motilal Oswal, Shaily has already been selected as sole supplier for most of these GLP-1 engagements.
The financial projections reflect the scale of the opportunity. Healthcare currently accounts for roughly 10% of Shaily's revenue. By fiscal 2028, that segment is expected to reach nearly Rs 880 crore, growing at a 50% compound annual rate and potentially comprising more than half of total company revenue. The margins in healthcare manufacturing are substantially higher than traditional plastics work, which underpins the brokerage's bullish case. Fiscal 2026 results — 82% net profit growth, EBITDA margins expanding to 28.2% — suggest the momentum is already real.
Shaily is also exploring adjacent opportunities in consumer electronics and semiconductor components, and plans a Rs 500 crore fundraising round to fund longer-term bets. But the brokerage is clear-eyed about the risk: valuations have already moved significantly, and the entire thesis rests on the company's ability to scale healthcare manufacturing at the pace and margins the market now expects. The 26% upside and the execution risk are, as ever, two sides of the same coin.
Motilal Oswal has initiated coverage of Shaily Engineering Plastics with a buy recommendation and a target price of Rs 3,404, suggesting the stock has room to climb 26% from current levels. The call reflects a deeper shift happening inside the company—one that transforms it from a maker of plastic components for consumer goods into a specialized manufacturer of medical devices riding the wave of a global obesity and diabetes treatment boom.
For nearly four decades, Shaily has supplied precision plastic parts to household names: IKEA, Unilever, Procter & Gamble, Gillette, General Electric. The work was steady, the margins modest. But inside the healthcare division, something more consequential is taking shape. The company now manufactures complex injection delivery devices—insulin pens, GLP-1 pens—the kind of equipment that pharmaceutical companies need to deliver their drugs to patients. It is one of a select group of global players with the expertise to make these products, and that positioning matters enormously in what comes next.
The catalyst is patent expiry. Semaglutide, the active ingredient in blockbuster weight-loss and diabetes drugs, loses patent protection in India, Brazil, and Canada starting in March 2026. When that happens, generic manufacturers will flood those markets with cheaper versions. They will need injection devices to deliver them. Shaily has already been selected as the sole device supplier for most of these GLP-1 engagements, according to the Motilal Oswal report. The company plans to invest more than Rs 600 crore to expand capacity and meet the demand.
The financial projections are striking. Healthcare currently contributes roughly 10% of Shaily's revenue. By fiscal 2028, Motilal Oswal expects that segment to reach nearly Rs 880 crore in sales, growing at a 50% compound annual rate. By that point, healthcare could account for more than half of the company's total revenue. The margins in this business are substantially higher than traditional plastics manufacturing, which explains why the brokerage sees such upside.
The company's recent performance supports the thesis. In fiscal 2026, Shaily grew revenue 26% year-over-year. EBITDA and net profit rose 59% and 82%, respectively. EBITDA margins expanded to 28.2% from 22.4% the prior year. Motilal Oswal expects this momentum to persist as healthcare volumes ramp and the company gains operating leverage across its expanded footprint.
There are other possibilities on the horizon. Shaily is exploring opportunities in consumer electronics and semiconductor component manufacturing—areas where its expertise in niche, complex plastic engineering could prove valuable. The company is also planning a Rs 500 crore fundraising round, capital that could fund these longer-term bets.
But the brokerage also sounds a note of caution. Valuations have already moved substantially higher. Any significant shortfall in execution—a missed quarter, a delayed contract, a manufacturing hiccup—could trigger a sharp repricing of the stock. The thesis is compelling, but it rests on the company's ability to scale healthcare manufacturing at the pace and margins the market now expects. For investors, that execution risk is the other side of the 26% upside coin.
Notable Quotes
Shaily is among select global players specializing in complex products such as IP-led insulin and GLP-1 pens— Motilal Oswal report
In most GLP-1 engagements, Shaily has been selected as the sole device supplier— Motilal Oswal report
The Hearth Conversation Another angle on the story
Why does a plastic components maker suddenly matter to investors in 2026?
Because the world is treating obesity and diabetes differently now. GLP-1 drugs are the fastest-growing pharmaceutical category globally. Every generic manufacturer entering those markets needs specialized injection devices. Shaily makes them.
But they've been making plastic parts for decades. What changed?
The healthcare division became the growth engine. It went from a small, steady business to the center of the company's future. Patent expiry in emerging markets is the trigger—it opens a massive market for generics, and those generics need devices.
Is Shaily the only company that can make these devices?
No, but they're one of very few with the expertise and capacity. More importantly, they've already been selected as the sole supplier for most GLP-1 engagements. That's a moat.
What's the financial picture?
Healthcare could be half the company's revenue by 2028, up from 10% now. Growing at 50% a year. The margins are much fatter than traditional plastics. That's why a 26% stock price target makes sense to the analysts.
What could go wrong?
Execution. If they can't scale manufacturing fast enough, or if the margins compress, or if a major contract falls through, the stock gets repriced downward. The thesis is solid, but it's not risk-free.
Is this a bet on GLP-1 drugs or on Shaily's ability to manufacture them?
Both. But really it's a bet on Shaily's ability to become the device supplier of choice as generic GLP-1s flood emerging markets. That's a very specific, very profitable position if they can hold it.